Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
7,733
result(s) for
"Embolism - etiology"
Sort by:
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation
In a large trial, the estimated incidence of stroke, systemic embolism, hemorrhage, or death was 2.8 percentage points lower to 0.5 percentage points higher with early than with later use of direct oral anticoagulants.
Journal Article
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
After atrial fibrillation ablation, left atrial appendage closure was associated with a lower risk of bleeding than oral anticoagulation and was noninferior to oral anticoagulation with respect to clinical outcomes at 36 months.
Journal Article
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
In a randomized trial involving patients with subclinical (typically asymptomatic) atrial fibrillation, apixaban led to a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding.
Journal Article
Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement
In a randomized trial involving patients with aortic stenosis, the use of a cerebral protection device during TAVR did not decrease the risk of periprocedural stroke, but there were fewer disabling strokes.
Journal Article
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
In patients with atrial high-rate episodes, edoxaban did not significantly reduce the incidence of stroke and cardiovascular outcomes as compared with placebo, but it led to a higher incidence of bleeding.
Journal Article
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
In a trial in patients with pelvic or acetabular fractures or extremity fractures that were treated operatively, aspirin thromboprophylaxis was noninferior to low-molecular-weight heparin in preventing death at 90 days.
Journal Article
Asundexian versus Apixaban in Patients with Atrial Fibrillation
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation.
Journal Article
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
In a trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events.
Journal Article
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
In this multicenter, randomized trial, edoxaban monotherapy led to a lower risk of net clinical adverse events at 12 months than dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.
Journal Article
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation
In a randomized trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner).
Journal Article